Supreme Court Denies Sequenom’s Petition for Certiorari

By Ron Kern on July 13, 2016 Posted in Uncategorized

On June 27, 2016, the U.S. Supreme Court, without comment, denied Sequenom’s petition for certiorari, leaving in place the Court’s previous rulings prohibiting the patenting of laws of nature and natural phenomenon. Read more >>… Continue Reading

Supreme Court Asked to Clarify Limits on Diagnostic Method Patents

By Ron Kern on April 18, 2016 Posted in Uncategorized

Arguing that the current state of the law weakens the patent system and poses a danger to life science innovators, biotechnology company, Sequenom, Inc., has filed a writ of certiorari with the U.S. Supreme Court, asking the Court to provide clarification regarding the limits of 35 U.S.C. § 101 as it relates to patent eligibility of diagnostic … Continue Reading

What Constitutes Patentable Subject Matter in Biotechnology?

By Maurice Valla on July 8, 2015 Posted in Uncategorized

With its recent (June 12, 2015) decision in Ariosa v. Sequenom, the Court of Appeals for the Federal Circuit affirmed the Northern District of California’s broad interpretation of the U.S. Supreme Court’s Prometheus v. Mayo holding that claims directed to the mere application of naturally occurring products and phenomena constitute unpatentable subject matter. Sequenom’s U.S. … Continue Reading